The introduction of radiolabelled antibodies targeting the lymphocyte antigen CD20 in certain hematologic malignancies received positive attention and is now accepted as a treatment modality. Treating solid tumours with radiolabelled antibodies has, so far, not been met with the same appreciation and such therapy for the large groups of malignancies like colorectal, breast, prostate, ovarian, lung cancer and brain tumours still require improvements in order to gain acceptance. In this chapter limitations, possibilities and future directions to improve therapy with radiolabelled antibodies are discussed. © 2008 Springer Science+Business Media B.V.
CITATION STYLE
Stigbrand, T., Eriksson, D., Riklund, K., & Johansson, L. (2008). Targeting tumours with radiolabeled antibodies. In Targeted Radionuclide Tumor Therapy: Biological Aspects (pp. 59–76). Springer Netherlands. https://doi.org/10.1007/978-1-4020-8696-0_4
Mendeley helps you to discover research relevant for your work.